Open access · CC-BY
via OpenAlex
mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging
Candice E. Van Skike, Ai‐Ling Lin, Raquel R Burbank, Jonathan J. Halloran, Stephen F. Hernandez, James Cuvillier, Vanessa Soto‐Cerrato, Stacy A. Hussong, Jordan B. Jahrling, Martin A. Javors, Matthew J. Hart, Kathleen E. Fischer, Steven N. Austad, Verónica Galván
Aging Cell · 2019 · ▲ 75 citations
Abstract
Cerebrovascular dysfunction and cognitive decline are highly prevalent in aging, but the mechanisms underlying these impairments are unclear. Cerebral blood flow decreases with aging and is one of the earliest events in the pathogenesis of Alzheimer's disease (AD). We have previously shown that the mechanistic/mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) drives disease progression in mouse models of AD and in models of cognitive impairment associated with atherosclerosis, closely recapitulating vascular cognitive impairment. In the present studies, we sought to determine whether mTOR plays a role in cerebrovascular dysfunction and cognitive decline during normative aging in rats. Using behavioral tools and MRI-based functional imaging, together with biochemical and immunohistochemical approaches, we demonstrate that chronic mTOR attenuation with rapamycin ameliorates deficits in learning and memory, prevents neurovascular uncoupling, and restores cerebral perfusion in aged rats. Additionally, morphometric and biochemical analyses of hippocampus and cortex revealed that mTOR drives age-related declines in synaptic and vascular density during aging. These data indicate that in addition to mediating AD-like cognitive and cerebrovascular deficits in models of AD and atherosclerosis, mTOR drives cerebrovascular, neuronal, and cognitive deficits associated with normative aging. Thus, inhibitors of mTOR may have potential to treat age-related cerebrovascular dysfunction and cognitive decline. Since treatment of age-related cerebrovascular dysfunction in older adults is expected to prevent further deterioration of cerebral perfusion, recently identified as a biomarker for the very early (preclinical) stages of AD, mTOR attenuation may potentially block the initiation and progression of AD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/acel.13057
- Canonical
- link ↗
- Fetched
- 2026-06-13 MST
Cite this
APA
Skike, C.E.V., Lin, A., Burbank, R.R., Halloran, J.J., Hernandez, S.F., Cuvillier, J., Soto‐Cerrato, V., Hussong, S.A., Jahrling, J.B., Javors, M.A., Hart, M.J., Fischer, K.E., Austad, S.N., & Galván, V. (2019). mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging. <em>Aging Cell</em>. https://doi.org/10.1111/acel.13057
Vancouver
Skike CEV, Lin A, Burbank RR, Halloran JJ, Hernandez SF, Cuvillier J, et al. mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging. Aging Cell. 2019. doi:10.1111/acel.13057.
BibTeX
@article{candice2019mTORdr,
title = {mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging},
author = {Candice E. Van Skike and Ai‐Ling Lin and Raquel R Burbank and Jonathan J. Halloran and Stephen F. Hernandez and James Cuvillier and Vanessa Soto‐Cerrato and Stacy A. Hussong and Jordan B. Jahrling and Martin A. Javors and Matthew J. Hart and Kathleen E. Fischer and Steven N. Austad and Verónica Galván},
journal = {Aging Cell},
year = {2019},
doi = {10.1111/acel.13057},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Neuroscience 2021
Open access · OA
mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer's Disease
PLoS ONE 2014
Open access · CC-BY
Long Leukocyte Telomere Length at Diagnosis Is a Risk Factor for Dementia Progression in Idiopathic Parkinsonism
Current Opinion in Clinical Nutrition & Metabolic Care 2014
Citation only
Cellular senescence and the senescent secretory phenotype in age-related chronic diseases
Nature Reviews Disease Primers 2021
Open access · OA
Parkinson disease-associated cognitive impairment
Gerontology 2018
Open access · OA
A Perfect sTORm: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review
American Journal of Physiology-Heart and Circulatory Physiology 2017
Open access · OA